Unintended consequences of treating early rectal cancers for complete clinical response with chemoradiotherapy
Author(s) -
Rob GlynneJones,
Neel Bhuva,
Mark Harrison
Publication year - 2020
Publication title -
colorectal cancer
Language(s) - English
Resource type - Journals
eISSN - 1758-1958
pISSN - 1758-194X
DOI - 10.2217/crc-2019-0010
Subject(s) - medicine , chemoradiotherapy , quality of life (healthcare) , colorectal cancer , sexual function , radiation therapy , population , colostomy , oncology , stage (stratigraphy) , anal cancer , surgery , intensive care medicine , cancer , nursing , paleontology , environmental health , biology
The aim was to examine the current trend in rectal cancer, which is to extend ’watch-and-wait’ to earlier-stage tumors, not normally treated with chemoradiotherapy, to define the up-side and down-side regarding quality of life (QOL) and anorectal/sexual/urinary function from this approach. We reviewed the literature regarding a ‘watch-and-wait’ strategy after neoadjuvant chemoradiotherapy. The primary outcome measure was complete clinical response. Secondary measures included colostomy rate, functional outcomes and QOL. There is a trend to use chemoradiotherapy in earlier tumors using dose-escalation of radiation and/or additional chemotherapy, resulting in high rates of complete clinical response, which may impact adversely on QOL if radical surgery is subsequently required. Focusing on organ-preservation as the primary goal of treatment rather than overall functional outcomes and QOL for the whole population, may not provide patients with sufficient information for optimal decision-making.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom